Rocket Pharmaceuticals, Inc. officer Martin Wilson filed a Form 144 notice on November 18, 2026, disclosing a proposed sale of 677 shares of common stock on NASDAQ under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Proposed sale: Wilson intends to sell 677 shares of Rocket Pharmaceuticals common stock, with an aggregate market value of $1,474.84.
  • Source of shares: The 677 shares were acquired on November 16, 2026, through restricted stock vesting from the issuer, with payment classified as compensation.
  • Tax-related purpose: According to the filing, "Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
  • Approximate sale date: The proposed sale is dated November 18, 2026, to be executed through Fidelity Brokerage Services LLC.
  • Shares outstanding: The filing states 111,660,283 shares of common stock were outstanding at the time of notice.
  • Prior sales in past 3 months: Wilson sold shares on four prior occasions: 631 shares on August 18, 2026 (gross proceeds $2,133.66); 75,364 shares on September 11, 2026 (gross proceeds $256,486.30); 53,389 shares on November 5, 2026 (gross proceeds $127,807.93); and 4,087 shares on November 13, 2026 (gross proceeds $9,196.98).

Wilson's Proposed Sale Follows Restricted Stock Vesting at Rocket Pharmaceuticals

Martin Wilson, identified in the filing as an officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), submitted a Form 144 notice dated November 18, 2026, disclosing a proposed sale of 677 shares of the company's common stock. The filing was submitted through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917. The aggregate market value of the proposed sale is listed as $1,474.84.

According to the filing, the 677 shares were acquired on November 16, 2026, via restricted stock vesting directly from the issuer. The nature of payment is listed as compensation. The filing includes a remark stating the sale is intended to cover a tax obligation arising from the settlement of a vested equity award distribution, a purpose the filer disclosed directly in the remarks section.

The filing also details Wilson's sales activity over the prior three months. Those transactions total 133,471 shares sold across four separate dates, generating combined gross proceeds of $395,624.89, as reported in the filing. Rocket Pharmaceuticals is headquartered at 350 Fifth Avenue, Suite 7530, New York, NY 10118, and the filing lists the company's SEC file number as 001-36829.

What Was Disclosed

A Form 144 notice was filed on November 18, 2026, by Rocket Pharmaceuticals officer Martin Wilson, covering a proposed sale of 677 shares of common stock acquired through restricted stock vesting, with the stated purpose of satisfying a tax obligation from a vested equity award.